Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis.
Ching THW, Stahnke B, Shnayder S, Agin-Liebes G, Adams TG, Amoroso L, Baiz O, Belser A, Bohner C, Burke M, D'Amico E, DePalmer G, Eilbott J, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk SA, Martins B, Purohit P, Schaer H, Sierra YP, Witherow C, Pittenger C, Kelmendi B
Publication record · Explore literaturePublic tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.
References — this paper cites (0)
No references identified in the available metadata. This does not establish that none exist.
Cited by — these papers cite this paper (4)
- Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD 2026-09-08 · Expand citations
- Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review 2026-07-01 · Expand citations
- A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder 2026-05-01 · Expand citations
- Case Report: Repeated low doses of psilocybin reduce perceived symptom severity but fail to restore cognitive flexibility in a case of severe obsessive-compulsive disorder: an observational case study of identical twins 2026-04-21 · Expand citations